Trabikibart
Trabikibart (CSL311), a βc (CSF2RB) -specific, fully human monoclonal antibody, binds to a unique epitope that is specific to the cytokine-binding site of the human βc receptor. Trabikibart has picomolar binding affinity for the human βc receptor. Trabikibart is a potent inhibitor of the combined effects of IL-3, GM-CSF and IL-5 on the survival of eosinophils. Trabikibart has the potential for chronic inflammatory diseases research[1].
Product Specifications
CAS Number
2643974-98-3
Product Name Alternative
CSL311
UNSPSC
12352203
Target
C-Fms
Type
Inhibitory Antibodies
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/trabikibart.html
Purity
99.17
Solubility
10 mM in DMSO
Smiles
[Trabikibart]
Molecular Weight
(144.66 kDa)
References & Citations
Shipping Conditions
Dry Ice
Storage Conditions
-80°C
Scientific Category
Inhibitory Antibodies
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Colloidal Gold Conjugated Goat Affinity Purified Antibody to Cat IgG, Fc Specific, 20nm
CD86 (Dendritic Cells Maturation Marker) (rC86/1146), CF405S conjugate, 0.1mg/mL
